Hepatic resection for recurrent metastatic ovarian carcinoma or peritoneal carcinoma: a retrospective case-control study

Purpose of investigation: This study was performed to investigate the validity of hepatic resection as a treatment option for hepatic parenchymal metastasis in patients with recurrent epithelial ovarian carcinoma or primary peritoneal carcinoma. Materials and Methods: A retrospective case-control study was conducted. Fisher’s exact test and Kaplan-Meier analysis were used to analyze the clinicopathologic characteristics and survival of 40 patients with hepatic parenchymal metastasis from recurrent ovarian carcinoma or primary peritoneal carcinoma. Results: Of these 40 patients, 12 characterized by unilobar metastasis underwent hepatic resection as part of secondary cytoreductive surgery, while 28 underwent only salvage chemotherapy. The median overall survival time from the time of the liver metastasis was significantly longer in patients who underwent hepatic resection as part of secondary cytoreduction than those who underwent salvage chemotherapy (62 vs. 14 months, respectively; p = 0.04). Conclusion: Hepatic resection has the potential to improve survival for patients with hepatic parenchymal metastasis from recurrent ovarian carcinoma or primary peritoneal carcinoma.

Hepatic resection; Ovarian carcinoma; Recurrence; Survival

[1] Coleman R.L., Monk B.J., Sood A.K., Herzog T.J.: “Latest research and treatment of advanced-stage epithelial ovarian cancer”. Nat. Rev. Clin. Oncol., 2013, 10, 211.

[2] Lorusso D., Mancini M., Di Rocco R., Fontanelli R., Raspagliesi F.: “The role of secondary surgery in recurrent ovarian cancer”. Int. J. Surg. Oncol., 2012, 2012, 613980.

[3] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[4] Cannistra S.A.: “Cancer of the ovary”. N. Engl. J. Med., 2004, 351, 2519.

[5] Bristow R.E., Puri I., Chi D.S.: “Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis”. Gynecol. Oncol., 2009, 112, 265.

[6] Fong Y., Blumgart L.H.: “Hepatic colorectal metastasis: current status of surgical therapy”. Oncology. (Williston Park), 1998, 12, 1489.

[7] Musunuru S., Chen H., Rajpal S., Stephani N., McDermott J.C., Holen K., et al.: “Metastatic neuroendocrine hepatic tumors: resection improves survival”. Arch. Surg., 2006, 141, 1000.

[8] Kazanjian K.K., Reber H.A., Hines O.J.: “Resection of pancreatic neuroendocrine tumors: results of 70 cases”. Arch. Surg., 2006, 141, 765.

[9] de Ridder J.A., van der Stok E.P., Mekenkamp L.J., Wiering B., Koopman M., Punt C.J., et al.: “Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection”. Eur. J. Cancer., 2016, 59, 13.

[10] Lim M.C., Kang S., Lee K.S., Han S.S., Park S.J., Seo S.S., Park S.Y.: “The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer”. Gynecol. Oncol., 2009, 112, 28.

[11] Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., Karlan B.Y.: “Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer”. Gynecol. Oncol., 1999, 72, 278.

[12] Chi D.S., Fong Y., Venkatraman E.S., Barakat R.R.: “Hepatic resection for metastatic gynecologic carcinomas”. Gynecol. Oncol., 1997, 66, 45.

[13] Merideth M.A., Cliby W.A., Keeney G.L., Lesnick T.G., Nagorney D.M., Podratz K.C.: “Hepatic resection for metachronous metastases from ovarian carcinoma”. Gynecol. Oncol., 2003, 89, 16.

[14] Abood G., Bowen M., Potkul R., Aranha G., Shoup M.: “Hepatic resection for recurrent metastatic ovarian cancer”. Am. J. Surg., 2008, 195, 370.

[15] Roh H.J., Kim D.Y., Joo W.D., Yoo H.J., Kim J.H., Kim Y.M., et al.: “Hepatic resection as part of secondary cytoreductive surgery for recurrent ovarian cancer involving the liver”. Arch. Gynecol. Obstet., 2011, 284, 1223.

[16] Burton E., Chase D., Yamamoto M., de Guzman J., Imagawa D., Berman M.L.: “Surgical management of recurrent ovarian cancer: the advantage of collaborative surgical management and a multidisciplinary approach”. Gynecol. Oncol., 2011, 120, 29.

[17] Calvert A.H., Newell D.R., Gumbrell L.A., O’Reilly S., Burnell M., Boxall F.E., et al.: “Carboplatin dosage: prospective evaluation of a simple formula based on renal function”. J. Clin. Oncol., 1989, 7, 1748.

[18] Berek J.S., Hacker N.F., Lagasse L.D., Nieberg R.K., Elashoff R.M.: “Survival of patients following secondary cytoreductive surgery in ovarian cancer”. Obstet. Gynecol., 1983, 61, 189.

[19] Yoon S.S., Jarnagin W.R., Fong Y., DeMatteo R.P., Barakat R.R., Blumgart L.H., Chi D.S.: “Resection of recurrent ovarian or fallopian tube carcinoma involving the liver”. Gynecol. Oncol., 2003, 91, 383.

[20] Loizzi V., Rossi C., Cormio G., Cazzolla A., Altomare D., Selvaggi L.: “Clinical features of hepatic metastasis in patients with ovarian cancer”. Int. J. Gynecol. Cancer., 2005, 15, 26.

[21] Bacalbasa N., Dima S., Brasoveanu V., David L., Balescu I., Purnichescu-Purtan R., Popescu I.: “Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit”. World. J. Surg. Oncol., 2015, 13, 235.

[22] Scarabelli C., Gallo A., Carbone A.: “Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma”. Gynecol. Oncol., 2001, 83, 504.

[23] Kolev V., Pereira E.B., Schwartz M., Sarpel U., Roayaie S., Labow D., et al.: “The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer”. Int. J. Gynecol. Cancer, 2014, 24, 70.